Status:
COMPLETED
Infective Endocarditis in Percutaneous Pulmonary Revalvulation: Comparison Between Melody and Sapien Valves
Lead Sponsor:
Centre Chirurgical Marie Lannelongue
Conditions:
Infective Endocarditis
Congenital Heart Disease
Eligibility:
All Genders
Brief Summary
Percutaneous pulmonary valve revalvulation (PPVR) has emerged as an alternative to surgery for the treatment of congenital heart disease with right ejection pathway dysfunction. The Melody valve (Medt...
Detailed Description
Infective endocarditis (IE) is a dreaded complication in patients with congenital heart disease (CHD), with an incidence up to 100-fold compared to the general population. In CHD such as cono-truncal ...
Eligibility Criteria
Inclusion
- Minor or adult patients who have undergone a successful percutaneous pulmonary revalvulation procedure
- Patients or legal guardians who do not object to the use of their data for this research.
Exclusion
- Patients under guardianship or curatorship
- Patient deprived of liberty
- Patient under court protection
- Patient or legal guardian objecting to the use of his or her data for this research
Key Trial Info
Start Date :
December 17 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06186258
Start Date
December 17 2021
End Date
July 31 2023
Last Update
December 29 2023
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Bordeaux
Bordeaux, France, 33000
2
CHU de Grenoble
Grenoble, France, 38500
3
Hopital Marie Lannelongue
Le Plessis-Robinson, France, 92350
4
CHRU Lille
Lille, France, 59000